Semaglutide (Ozempic) for Obesity: Pros and Cons

What is it about?

This article examines the advantages and disadvantages of using Ozempic (semaglutide) in the treatment of obesity. It employs an integrative analysis, collating findings from various scientific articles. The inclusion criteria encompassed keywords, publication language, and articles available on selected platforms such as Scielo, PubMed, and RDU. Conversely, exclusion criteria applied to incomplete or off-topic research lacking explicit methods and results. The study reveals that Ozempic, initially developed for type 2 diabetes mellitus, yields positive results in assisting obese patients with weight loss. Factors contributing to weight loss include proper medication dosage, improved energy intake, and reduced preference for fatty foods. These aspects are considered advantages. However, drawbacks are also identified. Ozempic is relatively new in the market, which limits scientific research into its long-term effects. Some researchers have speculated a causal link between semaglutide use and thyroid cancer in rodents, although this hasn't been confirmed in humans, it remains a potential disadvantage. In conclusion, Ozempic shows promise for weight loss, but the long-term side effects remain uncertain. This uncertainty poses a risk to patients utilizing Ozempic for obesity treatment.

Featured Image

Photo by Luke Michael on Unsplash

Photo by Luke Michael on Unsplash

Why is it important?

The importance of this article lies in its exploration of Ozempic (semaglutide) as a potential treatment for obesity, a global health concern with significant implications. Obesity, characterized by excessive body fat accumulation, leads to various health issues, including metabolic disturbances, respiratory difficulties, impaired mobility, and increased susceptibility to conditions like type 2 diabetes, cardiovascular diseases, and certain cancers. Understanding the advantages and disadvantages of Ozempic in the context of obesity treatment is crucial due to the rising prevalence of obesity worldwide. In Brazil, for instance, statistics from 2019 indicate that over 25% of the population is considered obese. Given the profound impact of obesity on quality of life, societal prejudice, and mortality rates, it's paramount to evaluate any potential therapeutic options. Ozempic's ability to aid weight loss, as highlighted in this study, is promising. However, its newness in the market raises questions about its long-term safety and side effects. The potential link between semaglutide use and thyroid cancer in animal studies underscores the need for thorough research before widespread adoption. This article serves as a valuable resource for healthcare professionals, researchers, and policymakers grappling with the obesity epidemic. It underscores the necessity of balanced assessments when considering Ozempic as a treatment option for obese individuals and highlights the need for continued investigation into its safety profile. KEY TAKEAWAY: Ozempic (semaglutide) shows promise in aiding weight loss for obese individuals, but its long-term safety remains uncertain. While it offers advantages, including improved energy intake and reduced preference for fatty foods, its newness in the market limits scientific research. Potential links to thyroid cancer in rodents warrant further investigation before widespread use.